PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

the Application of

Sylvain FLEURY et al.

Application No.: 10/573,704

Filed: March 27, 2006

Docket No.: 122481

For:

NEW SOLUBLE AND STABILIZED TRIMERIC FORM OF GP41 POLYPEPTIDES

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- \boxtimes This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- 冈 Relevance of one or more non-English language reference is discussed in the present specification. See References 1 and 10.
- \boxtimes One or more reference cited herein was cited in a counterpart foreign application. An English language version of the foreign search report is attached for the Examiner's information. See References 2-9.
- \bowtie In accordance with 37 CFR §1.98(a)(2)(ii), copies of any U.S. patents and patent application publications are not attached.

 \boxtimes 5. Reference 1 corresponds to reference 3.

Respectfully submitted,

Registration No. 27,075

Stephen P. Catlin Registration No. 36,101

JAO:SPC/aha

Date: October 20, 2006 OLIFF & BERRIDGE, PLC P.O. Box 19928 Alexandria, Virginia 22320 Telephone: (703) 836-6400

DEPOSIT ACCOUNT USE AUTHORIZATION Please grant any extension necessary for entry; Charge any fee due to our Deposit Account No. 15-0461 Sheet 1 of 1

Form PTO-14 (REV. 1/06)	49	US Dept. of Commerce PATENT & TRADEMARK OFFICE			ATTY DOCKET NO. 122481			APPLICATION NO. 10/573,704	
INFORMATION DISCLOSURE STATEMENT									
(Use several sheets if necessary)					APPLICANT(S) Sylvain FLEURY et al.				
					ILING DATE farch 27, 2006				
U.S. PATENT DOCUMENTS									
Examiner Initials	Cite No.	Document Number	Date		Name				
	1	6,455,265 B1	09/24/2002		Serres				
	FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Document Number	Date		· Country		With English Abstract	With English Translation	
	2	WO 02/34909 A2	05/02/2002		WIPO				
·	3	WO 99/25377 A1	05/27/1999		WIPO				
	,								
OTHER DOCUMENTS									
Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)							
	4	Louis J M, et al; (2001); "Design and Properties of Nccg-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion							
		Inhibitory Activity"; Journal of Biological Chemistry; vol. (276); pp. 29485-29489.							
	5	Eckert D M, et al; (2001); "Design of Potent Inhibitors of HIV-1 Entry From the gp41 N-peptide Region"; Proceedings of							
		the National Academy of Science of USA; vol. (98); pp. 11187-11192.							
	6	Root M J, et al; (2001); "Protein Design of an HIV-1 Entry Inhibitor"; Science; vol. (291); pp. 884-888.							
	7	Lu M, et al; (1999); "Subdomain Folding and Biological Activity of the Core Structure from Human Immunodeficiency Virus							
		Type 1 gp41: Implications for Viral Membrane Fusion"; Journal of Virology; vol. (73); pp.4433-4438.							
	8	Serres P F, "Molecular Mimicry Between the Trimeric Ectodomain of the Transmembrane Protein of Immunosuppressive							
		Lentiviruses (HIV-SIV-FIV) and Interleukin 2"; Life Sciences; vol. (323); pp. 1019-1029.							
•	9	Serres P F; (2001); "AIDS: an Immune Response Against the Immune System. Role of a Precise Tridimensional Molecular							
		Mimicry"; Journal of Autoimmunity; vol. (16); pp. 287-291.							
	10	Cavaillon J M, (1966); "Le Monde Des Cytokines"; pp. 1-12.							
EXAMINER						DATE CONSIDERED			
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

Date: October 20, 2006